New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.

RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Gelila Yoseph

Coordinator, Marketing and Communications

Gelila earned her B.A. in Design Studies from Marymount University and brings several years of experience across marketing, including graphic design, content strategy, campaign creation, and client relationship management.

What excites Gelila most about her work at NephCure is learning from patient stories and making a positive contribution to the rare kidney disease community through her work. She is deeply motivated by work that creates real impact and helps improve people’s lives.

Outside of work, Gelila enjoys reading books, sketching art, trying new restaurants and coffee shops, and spending quality time with friends and family.

Atlanta, GA

Related News

NEWS

NephCure Celebrates C3G Awareness Day on September 25, 2026

NEWS

NephCure Specialist of the Month: Dr. Rupali Avasare

NEWS

Making History on Capitol Hill: Record Advocates Unite for NephCure’s Largest Hill Day Ever

NEWS

NephCure Specialist of the Month: Dr. Fahad Aziz

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.